Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
52
NCT03111238
The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM
Phase: Phase 3
Role: Lead Sponsor
Start: Apr 5, 2017
Completion: Mar 31, 2021
NCT03174522
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
Start: Apr 25, 2017
Completion: Feb 13, 2023